Zimmer Biomet Holdings Inc (ZBH) : Anchor Capital Advisors reduced its stake in Zimmer Biomet Holdings Inc by 3.25% during the most recent quarter end. The investment management company now holds a total of 722,216 shares of Zimmer Biomet Holdings Inc which is valued at $84,817,047 after selling 24,274 shares in Zimmer Biomet Holdings Inc , the firm said in a disclosure report filed with the SEC on May 9, 2016.Zimmer Biomet Holdings Inc makes up approximately 2.16% of Anchor Capital Advisors’s portfolio.
Other Hedge Funds, Including , Ftb Advisors boosted its stake in ZBH in the latest quarter, The investment management firm added 85 additional shares and now holds a total of 1,951 shares of Zimmer Biomet Holdings Inc which is valued at $229,125. Zimmer Biomet Holdings Inc makes up approx 0.03% of Ftb Advisors’s portfolio.Bbva Compass Bancshares Inc reduced its stake in ZBH by selling 12,818 shares or 76.72% in the most recent quarter. The Hedge Fund company now holds 3,890 shares of ZBH which is valued at $448,906. Zimmer Biomet Holdings Inc makes up approx 0.03% of Bbva Compass Bancshares Inc’s portfolio.First Mercantile Trust Co reduced its stake in ZBH by selling 1,225 shares or 12.69% in the most recent quarter. The Hedge Fund company now holds 8,427 shares of ZBH which is valued at $975,594. Zimmer Biomet Holdings Inc makes up approx 0.12% of First Mercantile Trust Co’s portfolio.Stoneridge Investment Partners reduced its stake in ZBH by selling 1,700 shares or 3.21% in the most recent quarter. The Hedge Fund company now holds 51,298 shares of ZBH which is valued at $5,938,769. Zimmer Biomet Holdings Inc makes up approx 0.86% of Stoneridge Investment Partners’s portfolio.Everett Harris Co Ca reduced its stake in ZBH by selling 3,525 shares or 3.07% in the most recent quarter. The Hedge Fund company now holds 111,440 shares of ZBH which is valued at $12,901,409. Zimmer Biomet Holdings Inc makes up approx 0.46% of Everett Harris Co Ca’s portfolio.
Zimmer Biomet Holdings Inc (ZBH) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $117.09 and reached the intraday high at $118.61. The bulls started the profit booking and pushed the shares to intraday low of $116.61. The trading session was marked by a volume range of 16,67,020 shares exchanging hands. The 52-week high of the shares is $118.61 and the 52-week low is $88.27. The market cap of the company stands at $23,399 M and there are 19,92,38,890 shares in public circulation.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.93. The company had revenue of $1904.00 million for the quarter, compared to analysts expectations of $1878.31 million. The company’s revenue was up 67.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.54 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Barclays on Apr 29, 2016 to “Overweight”, Firm has raised the Price Target to $ 135 from a previous price target of $130 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 132 from a previous price target of $120 .Zimmer Biomet Holdings Inc was Initiated by Nomura to “Buy” on Mar 17, 2016.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.